Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.
about
Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap RegionHuman immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 yearsA novel substrate-based HIV-1 protease inhibitor drug resistance mechanismDifferential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CA recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirModulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacityFormation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Infectivity of Homologous Recombinant HIV-1 Pseudo-virus with Reverse Transcriptase Inhibitor-related Mutations from Highly Active Antiretroviral Therapy Experienced PatientsMolecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.Precise identification of a human immunodeficiency virus type 1 antigen processing mutant.Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antImpact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
P2860
Q27650299-BC4F807A-E516-4585-B6FD-F447A4439A56Q28379519-3DB22189-669B-4A43-8132-F871B8B896C5Q28469113-FF68E9D2-30B8-4D07-866E-53605AFE2E82Q28484213-23F3C962-1428-4CCA-8FCE-AC6A3ED1AD80Q32157822-BD86CC05-26BD-4F81-B26E-A728DDBEA293Q33657585-26AC56CD-1202-484A-81A7-BC161A2D4179Q33961507-56DCB4E5-C33A-450E-9DB9-4701552F9260Q33981401-F84C88D2-A194-4696-8EB8-79A66517C796Q34976619-54CABACA-DE65-4B18-9D70-92BAACF4848AQ35912746-A52E2D42-EACD-4D88-878D-001FB85B4292Q35950846-0177B13D-4BCB-45C5-B1B6-5FBE8DFF6EF4Q36928993-B299B392-9D49-48CD-A9F8-3074A6AD5FCDQ37155694-E2D0A0E4-B5D7-4F01-9176-E6988DD0E14EQ38344427-133ACEB0-33D3-4CC3-8CF6-0365FCC1CFD6Q38549717-60058981-D058-48BD-9284-D601C5AE31A1Q39459306-F5A1C13E-43AC-4764-BF64-C5935BD54725Q39556617-D9878D06-0558-478B-8C3F-88A292B8BE39Q39557921-729AA786-1895-413C-9196-385A85C368ACQ39651695-A0E5E4B5-E024-477F-8484-D643EBC0F623Q39652300-D4E2ACA5-83ED-4977-94DC-C373E79A3335Q39657878-A2CE3099-9693-443B-B372-1E8EAC8B43AEQ40013658-25E09283-B322-4C43-8945-A2A2DD419F9CQ40706086-190B52D0-A20C-446E-B6D9-CD38F5B49619Q40902737-F3ED6C84-2C10-4EC7-A90A-45E9A8A522A3Q41859612-55E00213-5D3C-4C20-A05D-41B91AF40D0EQ41928139-125FAC86-A7E9-4086-9606-E7C2D7377399Q42148219-539096FD-1A06-478A-AF02-AD9A8F565062Q47172282-0EF987CE-FCD0-4318-B625-82345C754950
P2860
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Human immunodeficiency virus t ...... ested in a cell-killing assay.
@en
Human immunodeficiency virus t ...... ested in a cell-killing assay.
@nl
type
label
Human immunodeficiency virus t ...... ested in a cell-killing assay.
@en
Human immunodeficiency virus t ...... ested in a cell-killing assay.
@nl
prefLabel
Human immunodeficiency virus t ...... ested in a cell-killing assay.
@en
Human immunodeficiency virus t ...... ested in a cell-killing assay.
@nl
P2093
P2860
P1476
Human immunodeficiency virus t ...... ested in a cell-killing assay.
@en
P2093
C A Boucher
M D de Jong
P Schipper
T van Bommel
P2860
P304
P407
P577
1996-10-01T00:00:00Z